- Home
- FEMY vs APRE Comparison
FEMY vs APRE Comparison
Compare FEMY & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- APRE
- Stock Information
- Founded
- FEMY 2004
- APRE 2006
- Country
- FEMY United States
- APRE United States
- Employees
- FEMY N/A
- APRE N/A
- Industry
- FEMY Medical/Dental Instruments
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FEMY Health Care
- APRE Health Care
- Exchange
- FEMY Nasdaq
- APRE Nasdaq
- Market Cap
- FEMY 24.9M
- APRE 21.3M
- IPO Year
- FEMY 2021
- APRE 2019
- Fundamental
- Price
- FEMY $1.01
- APRE $3.36
- Analyst Decision
- FEMY Strong Buy
- APRE Strong Buy
- Analyst Count
- FEMY 3
- APRE 2
- Target Price
- FEMY $10.00
- APRE $15.50
- AVG Volume (30 Days)
- FEMY 245.5K
- APRE 18.8K
- Earning Date
- FEMY 11-12-2024
- APRE 11-07-2024
- Dividend Yield
- FEMY N/A
- APRE N/A
- EPS Growth
- FEMY N/A
- APRE N/A
- EPS
- FEMY N/A
- APRE N/A
- Revenue
- FEMY $1,260,643.00
- APRE $1,310,839.00
- Revenue This Year
- FEMY $135.27
- APRE $116.72
- Revenue Next Year
- FEMY $310.75
- APRE N/A
- P/E Ratio
- FEMY N/A
- APRE N/A
- Revenue Growth
- FEMY 15.33
- APRE 130.31
- 52 Week Low
- FEMY $0.73
- APRE $2.15
- 52 Week High
- FEMY $2.40
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- FEMY 34.33
- APRE 41.12
- Support Level
- FEMY $0.98
- APRE $3.15
- Resistance Level
- FEMY $1.18
- APRE $4.15
- Average True Range (ATR)
- FEMY 0.08
- APRE 0.32
- MACD
- FEMY -0.03
- APRE -0.11
- Stochastic Oscillator
- FEMY 4.76
- APRE 11.76
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.